Evaluating Garlic Compound and Medication Combo for Treating Leishmaniasis

Greg Howard
31st August, 2024

Evaluating Garlic Compound and Medication Combo for Treating Leishmaniasis

Electron microscope images show that combining the garlic compound diallyl sulfide (c) with the standard drug meglumine antimoniate (b) causes catastrophic internal damage to the disease-causing Leishmania major parasite (d), visually confirming why this combination therapy is much more effective at killing the parasite than either treatment used alone and compared to the healthy parasite control (a).

Image adapted from: Zarrinkar et al. / CC BY (Source)

Key Findings

  • The study by Kerman University of Medical Sciences explored the use of diallyl sulfide (DAS) from garlic, combined with meglumine antimoniate (MAT), against Leishmania major
  • DAS combined with MAT showed no cytotoxicity and had strong anti-leishmanial effects, especially against the clinical stage of the parasite
  • In animal models, the combination treatment significantly reduced lesion size and parasite load, showing promise as a safer and effective therapy for cutaneous leishmaniasis
Leishmaniasis is a severe parasitic disease caused by the protozoan Leishmania and transmitted by the bite of infected female sandflies. Affecting millions globally, it manifests primarily in two forms: visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). Despite the significant health burden, no safe and effective vaccine currently exists, and existing control strategies have proven environmentally harmful and impractical[1]. A recent study by Kerman University of Medical Sciences explores the potential of diallyl sulfide (DAS), a compound derived from garlic, in combination with meglumine antimoniate (MAT), a standard anti-leishmanial drug, as a novel therapeutic approach against Leishmania major. This study is particularly relevant given the context provided by earlier research. The World Health Organization's comprehensive review highlighted the widespread prevalence of leishmaniasis, with millions at risk and thousands of deaths annually[2]. The disease's management is complicated by factors such as treatment unresponsiveness, which is influenced by demographic, clinical, environmental, and genetic factors[3]. Moreover, current treatments are often toxic and painful, underscoring the need for safer and more effective alternatives[4]. The Kerman University study aimed to evaluate the efficacy of DAS, both alone and in combination with MAT, through in vitro and animal model experiments. The researchers focused on the binding affinity of DAS with key immune system elements, including inducible nitric oxide synthase (iNOS), interferon-gamma (IFN-ɣ), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-α). These components play crucial roles in the body's defense mechanisms against infections. The binding affinity was used to predict the predominant binding mode for molecular docking configurations, which helps in understanding how DAS interacts with these immune elements. The study found that DAS, when combined with MAT, displayed no cytotoxicity and exhibited potent anti-leishmanial activity, especially against the clinical stage of the parasite. The mechanism of action involved immunomodulation, which is the adjustment of the immune response to a desired level. This was achieved through the induction of Th1 cytokine phenotypes, which are types of signaling proteins that help in the immune response. The combination also triggered a high apoptotic profile, meaning it induced programmed cell death in the parasites, and increased the production of reactive oxygen species (ROS), which are chemically reactive molecules that play a role in cell signaling and homeostasis. Additionally, antioxidant enzymes were activated, which help in protecting cells from damage. In animal models, specifically BALB/c mice, the combination treatment significantly reduced the diameter of cutaneous lesions and the parasite load. Histopathological analysis, which involves the microscopic examination of tissue to study the manifestations of disease, showed infiltration of inflammatory cells associated with T-lymphocytes, particularly CD4+ phenotypes. These findings were supported by biochemical markers that indicated a reduction in the amastigote stage of the parasite and improvement in pathological changes in infected mice. The results of this study are promising and suggest that DAS and MAT could be further developed as a therapeutic option for CL. The combination treatment not only showed efficacy in reducing parasite load and lesion size but also demonstrated a favorable safety profile with no observed cytotoxicity. This aligns with previous findings that emphasize the need for novel, less toxic treatment options[4]. Moreover, the study's focus on immunomodulation and the activation of immune responses provides a new avenue for therapeutic strategies, addressing some of the gaps identified in earlier research[3]. In conclusion, the study by Kerman University of Medical Sciences provides a compelling case for the potential use of DAS in combination with MAT as a treatment for cutaneous leishmaniasis. Given the limitations of current treatments and the urgent need for safer and more effective options, this combination therapy deserves further investigation in clinical trials. This could potentially lead to a significant advancement in the management of leishmaniasis, offering hope to millions affected by this neglected tropical disease.

MedicineBiochemAnimal Science

References

Main Study

1) Assessment of the antileishmanial activity of diallyl sulfide combined with meglumine antimoniate on Leishmania major: Molecular docking, in vitro, and animal model.

Published 30th August, 2024

https://doi.org/10.1371/journal.pone.0307537

Related Studies

2) Leishmaniasis worldwide and global estimates of its incidence.

https://doi.org/10.1371/journal.pone.0035671

3) Determinants of Unresponsiveness to Treatment in Cutaneous Leishmaniasis: A Focus on Anthroponotic Form Due to Leishmania tropica.

https://doi.org/10.3389/fmicb.2021.638957

4) Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments.

https://doi.org/10.1007/s40257-022-00726-8


Related Articles

An unhandled error has occurred. Reload 🗙